Literature DB >> 8008701

Plasma factor triggering alternative complement pathway activation by liposomes.

K Funato1, C Yamashita, J Kamada, S Tominaga, H Kiwada.   

Abstract

Several plasma components, such as complement (C) components, play a role in the clearance of liposomes from the circulation. The interactions between liposomes and the C system were investigated in this study. Multilamellar vesicle (MLV) liposomes, which were damaged by activation of the complement, became susceptible depending on the density of cetylmannoside (Man) on the liposome membrane, and activation proceeded through the alternative C pathway as observed for liposomes without Man (PC-MLV) (K. Funato et al., Biochim. Biophys. Acta 1103:198-204, 1992). In addition, the capacity of Man-modified liposomes (Man-MLV) to activate the alternative C pathway was abolished by preadsorption of plasma with Man-MLV but not with PC-MLV. The results suggest that a specific plasma factor adsorbed with Man-MLV was responsible for the augmentation of the C activation and, further, that the rapid clearance of Man-MLV from the circulation is caused by both enhanced C-mediated liposome permeability and enhanced C-mediated phagocytosis of liposomes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8008701     DOI: 10.1023/a:1018952718496

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  29 in total

1.  Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans.

Authors:  M A Wilson; T R Kozel
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

2.  The C4 and C2 but not C1 components of complement are responsible for the complement activation triggered by the Ra-reactive factor.

Authors:  Y H Ji; M Matsushita; H Okada; T Fujita; M Kawakami
Journal:  J Immunol       Date:  1988-12-15       Impact factor: 5.422

3.  Application of synthetic alkyl glycoside vesicles as drug carriers. I. Preparation and physical properties.

Authors:  H Kiwada; H Niimura; Y Fujisaki; S Yamada; Y Kato
Journal:  Chem Pharm Bull (Tokyo)       Date:  1985-02       Impact factor: 1.645

4.  Activation of human complement by liposomes: serum factor requirement for alternative pathway activation.

Authors:  C Mold; H Gewurz
Journal:  J Immunol       Date:  1980-08       Impact factor: 5.422

5.  C3 shunt activation in human serum chelated with EGTA.

Authors:  D P Fine; S R Marney; D G Colley; J S Sergent; R M Des Prez
Journal:  J Immunol       Date:  1972-10       Impact factor: 5.422

Review 6.  Antibodies to cholesterol, cholesterol conjugates and liposomes: implications for atherosclerosis and autoimmunity.

Authors:  C R Alving; G M Swartz
Journal:  Crit Rev Immunol       Date:  1991       Impact factor: 2.214

7.  Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma.

Authors:  K Funato; R Yoda; H Kiwada
Journal:  Biochim Biophys Acta       Date:  1992-01-31

8.  Activation of the alternative complement pathway by water-insoluble glucans of streptococcus mutans: the relation between their chemical structures and activating potencies.

Authors:  S Inal; K Nagaki; S Ebisu; K Kato; S Kotani
Journal:  J Immunol       Date:  1976-10       Impact factor: 5.422

9.  Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes.

Authors:  A Chonn; S C Semple; P R Cullis
Journal:  J Biol Chem       Date:  1992-09-15       Impact factor: 5.157

10.  Interactions of liposomes with serum proteins.

Authors:  F Bonté; R L Juliano
Journal:  Chem Phys Lipids       Date:  1986 Jun-Jul       Impact factor: 3.329

View more
  1 in total

1.  Synergistic effect between size and cholesterol content in the enhanced hepatic uptake clearance of liposomes through complement activation in rats.

Authors:  H Harashima; T M Huong; T Ishida; Y Manabe; H Matsuo; H Kiwada
Journal:  Pharm Res       Date:  1996-11       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.